Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This work did not require ethical approval
Gutierrez & Simmen, 2018
GLP-1 receptor agonists may offer a new approach that can complement existing topical, systemic and biologic treatment options. Across the trials, clinicians treated participants with one of three GLP-1s 81.5% received semaglutide (Wegovy, Novo Nordisk), 17.4% received liraglutide and 1% received tirzepatide (Zepbound, Eli Lilly) at varying dosages and treatment durations
This matters because many products marketed as "GLP-1 patches" do not contain a GLP-1 receptor agonist at all
But the science is mostly animal-based, small-scale, or too weak to compare to prescription GLP-1 medications
US$ 22.62
US$ 21.22
US$ 24.16
US$ 21.84
US$ 25.65
US$ 25.59
US$ 26.78
